@article {CramerP6.283作者={乔伊斯克莱默和凯瑟琳·普兰特Anastassopoulos Krithika Rajagopalan和大卫·布卢姆},title ={预测因子的临床意义的成年人健康相关的生活质量的改善与部分性癫痫:汇集分析从两个醋酸Eslicarbazepine单一疗法试验(P6.283)},体积={90}={15}补充数量,elocation-id = {P6.283} ={2018},出版商= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={目的:评估潜在的预测实现最小的临床重要差异(MCID)成年人健康相关的生活质量(HRQoL)与部分性癫痫(POS)接收Eslicarbazepine醋酸(ESL)单药治疗。首页背景:成年人和经历频繁发作的POS HRQoL不良报告。HRQoL和MCID成就评估使用Epilepsy-31库存(QOLIE-31)的生活质量管理两个阶段3 dose-blind ESL conversion-to-monotherapy试验的成年人在基线与POS(2周开始滴定/六周锥/转换时期)和星期18(10周单药治疗期结束)。设计/方法:QOLIE-31改变从基线到星期18和患者的百分比变化> = MCIDs计算的患者进入滴定/转换时期(功效;N = 332),完成了滴定/转换时间(按方案;n = 268),仍在研究中通过最后一次访问(完成者;n = 226)。使用逻辑回归检查可能的预测因素(即。、基线发作频率、基线QOLIE-31得分,ESL剂量,年龄、体重指数、性别、种族、种族、地区)18周后MCID成就,基于发表MCIDs QOLIE-31总分(TS)和7子量表的分数。结果:疗效(n = 126)的人口一半得分QOLIE-31 (n = 252) QOLIE-31 TS MCID实现。能源/疲劳内部氧化物比例达到最低MCID(41.3 \ %),而社会功能最高(53.2 \ %)。最好的预测MCID成就是基线得分。5.4 \ %的几率增加单位降低TS MCID成就基线观察TS (p < 0.001)。 Among the 7 subscales, the increased odds of MCID achievement per unit decrease in baseline subscale score ranged from 2.4\% (p\<0.001) in cognitive functioning to 9.4\% (p\<0.001) in emotional well-being. Results were similar for per-protocol and completer populations.Conclusions: These results suggest that half of patients who initiated, converted to, or completed ESL monotherapy realized clinically meaningful QOLIE-31 improvements. Additionally, patients with poorer baseline QOLIE-31 had a greater likelihood of achieving MCIDs.Study Supported by: Sunovion Pharmaceuticals Inc.Disclosure: Dr. Cramer has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with UCB, Sunovion, Supernus, Sun, Liva-Nova. Dr. Anastassopoulos has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Covance Market Access Services. Dr. Rajagopalan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sunovion Pharmaceuticals Inc. Dr. Blum has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employment: Sunovion Pharmaceuticals Inc.}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/90/15_Supplement/P6.283}, eprint = {//www.ez-admanager.com/content}, journal = {Neurology} }